Expensify Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Expensify Inc trades at $2.3 (market cap $208.82M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 118.4× Expensify Inc's market cap, and Expensify Inc is more actively traded (456,102 versus 6,279,442). Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| EXFY | ROIV | |
|---|---|---|
Market Cap | $208.82M | $24.72B |
Volume | 456,102 | 6,279,442 |
Sector | Technology | Health |
52-Week High | $2.72 | $41.81 |
52-Week Low | $0.75 | $16.04 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | $148.44M | $20.99B |
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.27, up 1.79% with a neutral technical signal. The company shows mixed fundamentals with revenue stabilizing around $140M but persistent net losses. Recent quarters show earnings improvement with two beats, while analyst consensus is bullish with a $13.75 price target. Business developments include AI integrations and European expansion of corporate card offerings.
The outlook remains speculative given negative profitability metrics, though cash flow improvements and strategic partnerships provide potential catalysts. Key risks include competitive pressure in expense management and the challenge of achieving sustainable profitability. The significant gap between current price and analyst targets suggests upside potential if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →